BI-1206
BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL)[3].
Product Specifications
UNSPSC
12352203
Target
CD20; Fc Receptor (FcR)
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Smiles
[BI-1206]
References & Citations
[1]Jiang VC, et al., Targeting FcγRIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma. J Hematol Oncol. 2022 Apr 11;15 (1) :42. |[2]Changying Jiang, et al., BI-1206, a Monoclonal Antibody Against Fcγriib, Showed Superior Anti-Tumor Activity in an Ibrutinib-Venetoclax Dual Resistant PDX Model in Mantle Cell Lymphoma, Blood, Volume 134, Supplement 1, 2019, Page 2863, ISSN 0006-4971. |[3]Mårtensson, L.et al., A novel FcγRIIB-blocking antibody to enhance FcγR-dependent antitumor immunity with anti-HER2 therapy[J]. Cancer Research, 2022, 82 (12_Supplement) : 3423-3423.
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040525-500 1x 500 µL
CD63 (MX-49.129.5), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC471037-500 1x 500 µL
CD44 Standard (DF1485), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880257-100 1x 100 µL
Cytokeratin, HMW (AE-3), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC701619-100 1x 100 µL
CD9 (TSPAN29) (Motility-Related Protein-1) (CD9/1619), CF770 conjugate, 0.1mg/mL
Sign In for Pricing
View Details